free web stats

Your Drug Injury Case Will Benefit From Our Years of Experience


Experienced drug injury lawyer

Attorney Tom Lamb

We have been representing patients and their family in drug injury lawsuits for the past 16 years and this is our main practice area.

Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.

Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.

Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.

We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.

If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.

We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation.  Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case.  Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.

We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.

While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.

It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.


Legal & Medical News: Featured Article


Harvoni / Sovaldi Risks: Liver Cancer Return, Hepatitis B Reactivation

From this April 15, 2016 European Medicines Agency (EMA) News item, “Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 April 2016” we get an overview of a new drug safety issue involving the direct-acting antivirals class of drugs used for treating long-term, or chronic, hepatitis C:

At its previous meeting in March, the Committee had initiated a review following cases of hepatitis B re-activation in patients who have been infected with hepatitis B and C viruses, and who were treated with direct-acting antivirals for hepatitis C.

In April 2016, data from a study became available regarding the risk of liver cancer (hepatocellular carcinoma) coming back in patients who were treated with these medicines. The study suggested that these patients were at risk of their cancer coming back earlier than patients with hepatitis C who were not treated with direct-acting antivirals. The scope of the ongoing review has therefore been extended to also assess the risk of liver cancer with these medicines.

As for what this development means for US patients and physicians, Harvoni, Sovaldi, Daklinza, and Olysio are the implicated direct-acting antivirals currently approved by the FDA.

In addition, Viekira Pak (dasabuvir and ombitasvir and paritaprevir and ritonavir) — which is available for use here — seems to be a “combination-product” of the Exviera and Viekirax drugs which are listed in the EMA press release, above.

We have written in the past about Viekira Pak side effects in this October 2015 article, “Hepatitis C Drugs Viekira Pak And Technivie Require Warnings Label Changes Due To Liver Injury Reports”.

The current EMA Timetable for this PRAC safety review of Harvoni, Sovaldi, and the other new “hep-c” drugs has the current process coming to an end this summer.

Of course, we will be watching for results of safety review and report those out, here, when available.

[Read this article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
(800) 426-9535
[email protected]
Disclaimer and Copyright